Therefore, we postulate that the protective effect of BDNF Val66Met polymorphism on cognitive impairment is conditional on the presence of active malignancy or ongoing cancer treatment, both which have been hypothesized as possible causes of CRCI [25]. The gene discussed is BDNF; the disease is cancer.